Hotline for Health Services for Displaced Lebanese 1787
Hotline for the Patient Admission to Hospitals 01/832700
COVID-19 Vaccine Registration Form covax.moph.gov.lb
MoPH Hotline 1214
Are you a new member? Sign up now
 
Let us help you
Read about the latest topics.

Integration of Non-Communicable Disease Services within Primary Health Care

 
Introduction
The Primary Health Care Department at the Ministry of Public Health in collaboration with WHO, launched an initiative for the integration of Non-Communicable Diseases (NCD) program within Primary Health Care centers in Lebanon, in 2012. This initiative aimed at integrating a two-step early detection of Diabetes Mellitus and Hypertension as well as estimating the Total Cardiovascular Risk among beneficiaries aged 40 years and above. The model adopted in this initiative was based on the WHO’s 2012 package of Essential Non-Communicable Diseases interventions for Primary Health Care.
The two-step screening model consists of administering initially a screening tool by the health care workers whether in the setting of the health center or in the community. Step 1 consists of using this tool which is in the form of a questionnaire that tackles information related to the beneficiaries. The health care worker would then calculate the total cardiovascular risk for the beneficiary (using the WHO/International Society of Hypertension –WHO/ISH- risk prediction charts) and would refer him/her to the next step (Step 2) in case the total cardiovascular risk was greater than 10% or there was a previous history of diabetes or hypertension. Step 2 involves performing a set of laboratory tests and a referral to the treating physician for calculation of the final cardiovascular risk.
 
Development of the Non-Communicable Disease Program
The program has passed through many phases, in each phase many centers were trained on implementing and using the NCD programs tools and protocols. All the centers within the Primary Healthcare network were trained on NCD within the time period 2013 to 2017. Training sessions were done on regular basis including 25 centers per session. The training included the healthcare workers, nursing staff, administrative staff and physicians.
 
Continuous Support
In order to maintain the sustainability of the program, POINT OF CARE testing machines for NCD screening were distributed to all involved Primary Health Care centers.
Furthermore, to sustain the accuracy of the data entered daily by the centers, an NCD e module was developed by the IT MoPH department on the Health Information System to aid the centers to enter all the NCD related data and perform the calculations necessary for diagnosis of cardiovascular risks.
The MoPH encourages the Primary Health Care centers in Lebanon to organize outreach activities, events and campaigns to raise the awareness on health factors associated with cardiovascular diseases (CVDs), such as obesity, lack of physical activity and smoking (tobacco-use). MoPH provides educational material to support these activities.
 
    ...
    9
ATC Name B/G Ingredients Dosage Form Price
N03AX18 TREPADIO G Lacosamide - 10mg/ml 10mg/ml Syrup 948,753 L.L
L01AX03 TEMOZOLOMIDE PHARMINICIO G Temozolomide - 100mg 100mg Capsule, hard 4,511,279 L.L
L04AA29 TRIJAN G Tofacitinib - 5mg 5mg Tablet, film coated 54,863,315 L.L
N03AX18 TREPADIO G Lacosamide - 200mg/20ml 200mg/20ml Injectable solution 9,569,390 L.L
L01AX03 TEMOZOLOMIDE PHARMINICIO G Temozolomide - 20mg 20mg Capsule, hard 920,532 L.L
L04AA29 TRIJAN G Tofacitinib - 10mg 10mg Tablet, film coated 84,793,962 L.L
N02AX02 TRAMADOL DENK 50 G Tramadol HCl - 50mg 50mg Tablet, effervescent 256,674 L.L
L01AX03 TEMOZOLOMIDE ACCORD G Temozolomide - 20mg 20mg Capsule, hard 1,153,017 L.L
L01AX03 TEGOZOL G Temozolomide - 20mg 100mg Capsule 967,567 L.L
J01XA02 TEICO MEDIS 400 G Teicoplanin - 400mg 400mg Injectable lyophilised powder 1,157,048 L.L
L01AX03 TEMOZOLOMIDE ACCORD G Temozolomide - 5mg 5mg Capsule, hard 1,153,017 L.L
L04AA31 TERAGIO G Teriflunomide - 14mg 14mg Tablet 49,451,224 L.L
L01AX03 TEMOZOLOMIDE PHARMINICIO G Temozolomide - 5mg 5mg Capsule, hard 1,153,017 L.L
L04AA31 TERAGIO G Teriflunomide - 14mg 14mg Tablet 23,076,914 L.L
J01XA02 TEICO MEDIS 200 G Teicoplanin - 200mg 200mg Injectable lyophilised powder 428,686 L.L
G01AA51 TERGYNAN G Nystatin - 100000IU, Neomycin (sulfate) - 65000IU, Metronidazole - 500mg Tablet 348,055 L.L
J01DD04 TRAVILAN IM G Ceftriaxone (sodium) - 1g 1g Injectable lyophilised powder for solution+diluent 438,093 L.L
J01DD04 TRIAXONE G Ceftriaxone (sodium) - 1g 1g Injectable powder for solution 438,093 L.L
J01DD04 TRIAXONE G Ceftriaxone (sodium) - 1g 1g Injectable powder for solution 4,542,188 L.L
C09DA07 TELMICARD 80 PLUS G Telmisartan - 80mg, Hydrochlorothiazide - 12.5mg Tablet 954,768 L.L
D01AE15 TERAFAN G Terbinafine HCl - 1% 1% Cream 499,142 L.L
S01AA09 TETRACYCLINE EYE OINTMENT G Tetracycline HCl - 1% 1% Ointment 71,672 L.L
D01AE15 TERMINUS G Terbinafine HCl - 1% 1% Cream 747,176 L.L
S01AA12 TOBRACIN G Tobramycin - 0.3% 0.3% Drops 322,522 L.L
S01AA12 TOBRASTILL G Tobramycin - 0.3% 0.3% Drops solution 258,018 L.L
D01AE15 TERAFAN G Terbinafine HCl - 1% 1% Solution 355,798 L.L
S01AA12 TOBRIN G Tobramycin - 0.3% 0.3% Drops 169,324 L.L
S01AA12 TOBRACIN G Tobramycin - 0.3% 0.3% Ointment 280,863 L.L
D01BA02 TERAFAN G Terbinafine HCl - 250mg 250mg Tablet, scored 725,675 L.L
D01BA02 TERMINUS G Terbinafine HCl - 250mg 250mg Tablet 483,783 L.L
    ...
    9
Sitemap
© Copyrights reserved to Ministry of Public Health 2025